#healthcare
Total 15 articles
TriZetto confirms massive health data breach affecting 3.4 million people went undetected for nearly a year, exposing critical vulnerabilities in healthcare IT infrastructure.
Research from trauma centers reveals that medical teams with shared experience deliver significantly better patient outcomes. The science behind life-saving collaboration.
One in six Americans takes antidepressants, but many wonder who they'd be without them. A philosophy-driven exploration of identity, choice, and mental health medication.
PRISM by Liabooks
Place your ad in this space
[email protected]
A brain aneurysm, unpaid bills, and the impossible math of American healthcare. When prevention becomes a luxury, what's the real price we pay?
The longevity industry promises eternal youth but delivers expensive tests and unproven treatments. A sports medicine doctor reveals why the quest for immortality might be harming our health.
How digital twin technology is helping people manage diabetes and obesity without expensive GLP-1 drugs, and what it means for the future of healthcare.
New research reveals that carrying just one copy of a disease-causing gene mutation can still cause real health problems, challenging decades of medical assumptions.
PRISM by Liabooks
Place your ad in this space
[email protected]
DavaIndia's security flaw exposed customer prescription data and drug control functions, highlighting critical vulnerabilities in online healthcare platforms.
Despite GLP-1 drugs like Ozempic showing dramatic individual results, national obesity rates remain stubbornly unchanged. We examine why the weight-loss revolution hasn't reached population-level statistics.
The American Society of Plastic Surgeons recommends delaying gender surgeries until age 19, marking a paradigm shift in youth gender medicine as evidence gaps become undeniable.
Novo Nordisk sues Hims & Hers over knockoff weight-loss drugs. A David vs Goliath battle over patient access versus Big Pharma patents unfolds.
PRISM by Liabooks
Place your ad in this space
[email protected]
Merck and Pfizer earnings reveal the pharmaceutical industry's delicate balance between blockbuster dependency and pipeline innovation. What lies beneath the solid but unspectacular results?
